网站主页 化工产品目录 原料药
专科用药
眼科用药
1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI)
1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI)
1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI)
英文名称:1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI)
CAS号:849758-52-7
分子式:
分子量:0
EINECS号:
Mol文件:Mol File
1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI) 用途与合成方法
Bevasiranib sodium 是一种 siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。
1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI)供应商 更多
广州优南科技有限公司
联系电话:020-82000279 18988941452
产品介绍:
英文名称:Bevasiranib sodium
CAS:849758-52-7
纯度:95/98
包装信息:25mg;100mg;500mg;1g;5g
备注:更多规格可联系获取
上海梅凯科技有限公司
联系电话:021-68689288 15300790979
产品介绍:
英文名称:1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j′]diquinolizin-18-ium, 9-[2(or 4)-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-, inner salt (9CI, ACI)
CAS:849758-52-7
纯度:95%